Johnson & Johnson (JNJ) : Hexavest reduced its stake in Johnson & Johnson by 7.84% during the most recent quarter end. The investment management company now holds a total of 1,390,100 shares of Johnson & Johnson which is valued at $163,531,364 after selling 118,245 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Johnson & Johnson makes up approximately 2.98% of Hexavest’s portfolio.
Other Hedge Funds, Including , Thompson Rubinstein Investment Management Inc Or reduced its stake in JNJ by selling 1,245 shares or 1.63% in the most recent quarter. The Hedge Fund company now holds 75,284 shares of JNJ which is valued at $9,019,023. Johnson & Johnson makes up approx 3.44% of Thompson Rubinstein Investment Management Inc Or’s portfolio.New England Research Management boosted its stake in JNJ in the latest quarter, The investment management firm added 5,063 additional shares and now holds a total of 30,343 shares of Johnson & Johnson which is valued at $3,616,279. Johnson & Johnson makes up approx 3.05% of New England Research Management’s portfolio.First American Trust Fsb reduced its stake in JNJ by selling 490 shares or 0.77% in the most recent quarter. The Hedge Fund company now holds 63,125 shares of JNJ which is valued at $7,523,238. Johnson & Johnson makes up approx 2.36% of First American Trust Fsb’s portfolio.Lenox Wealth Advisors reduced its stake in JNJ by selling 48 shares or 5.29% in the most recent quarter. The Hedge Fund company now holds 859 shares of JNJ which is valued at $102,376. Johnson & Johnson makes up approx 0.03% of Lenox Wealth Advisors’s portfolio.
Johnson & Johnson closed down -2.16 points or -1.80% at $117.64 with 63,94,159 shares getting traded on Tuesday. Post opening the session at $119.41, the shares hit an intraday low of $117.06 and an intraday high of $119.63 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.